Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc HMTXF


Primary Symbol: V.HEM

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Post by Dudeforeveron Dec 07, 2023 4:52pm
411 Views
Post# 35773927

Ah, what will the New Year bring?

Ah, what will the New Year bring?2024 will either be HEM's last year, or else one of their many claims actually proves to have substance.  Thomas has drained his cup of credibility.  Raising money is going to be almost an impossibility.  They are going to have to dig their way out of this mess the old-fashioned way.  Work hard, deliver on what you promise, and make meaningful sales and partnerships.

When I parted with some of my hard-earned dough a few years ago, Thomas assured me that Phase 2 was complete except for some perfunctory paperwork, and Phase 3 was all smooth sailing and lollipops.  The lawsuit from former partners was a mere trifle.  Well, I'm a bit poorer, but a bit wiser.  

Good luck, Thomas.
<< Previous
Bullboard Posts
Next >>